SCHEMBL20149287

SCHEMBL20149287

CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(C)=O)O1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 11/20 0.85
▸ PGR P06401 6/20 0.85
▸ CYP3A4 P08684 3/20 0.85
▸ HIF1A Q16665 3/20 0.85
▸ LMNA P02545 2/20 0.85
▸ ABCC3 O15438 1/20 0.85
▸ ABCC4 O15439 1/20 0.85
▸ ABCB11 O95342 1/20 0.85
▸ IL5 P05113 1/20 0.85
▸ NR3C2 P08235 1/20 0.85
▸ AR P10275 1/20 0.85
▸ CHRM1 P11229 1/20 0.85
▸ MMP9 P14780 1/20 0.85
▸ NFKB1 P19838 1/20 0.85
▸ THPO P40225 1/20 0.85
▸ SMN1; SMN2 Q16637 1/20 0.85
▸ HSD17B10 Q99714 1/20 0.85
▸ BLM P54132 1/20 0.85
▸ PMP22 Q01453 1/20 0.85
▸ NPSR1 Q6W5P4 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12396748 0.94 NR3C1 (0.86) NR3C1PGRCYP3A4HIF1ALMNA
SCHEMBL12465053 0.94 NR3C1 (0.86) NR3C1PGRCYP3A4HIF1ALMNA
SCHEMBL7741860 0.94 NR3C1 (0.86) NR3C1PGRCYP3A4HIF1ALMNA
SCHEMBL20370199 0.93 NR3C1 (0.89) NR3C1PGRCYP3A4HIF1ALMNA
SCHEMBL20223507 0.93 NR3C1 (0.89) NR3C1PGRCYP3A4HIF1ALMNA
Dexbudesonide SCHEMBL141510 0.92 NR3C1 (0.97) NR3C1PGRCYP3A4HIF1ALMNA
Budesonide SCHEMBL14452945 0.92 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ALMNA
Budesonide SCHEMBL13695912 0.92 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ALMNA
Budesonide SCHEMBL16731476 0.92 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ALMNA
Budesonide SCHEMBL13871728 0.92 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10774059-B2 Compositions and methods for the treatment of inflammation CELLIX BIO PRIVATE LIMITED (IN) 2020-09-15 — — US disclosed
WO-2018089373-A9 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2018-07-12 — — WO disclosed
WO-2018089373-A2 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2018-05-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10774059-B2 Compositions and methods for the treatment of inflammation IL1B, IL36G, IL17A NR3C1 246/4885PGR 1809/4885CYP3A4 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback